92 completed, 41 terminated, 16 unknown, 12 recruiting. 69 Phase 1, 69 Phase 2, 15 Phase 3, 14 Not applicable, 2 Early Phase 1.
Follow Squamous Cell Carcinoma of the Head and Neck: new trials by email Literature Review of Squamous Cell Carcinoma of the Head and Neck trials Research Report on Squamous Cell Carcinoma of the Head and Neck
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypofractionated Radiotherapy in Older Adults With Head and Neck Squamous Cell Carcinoma Hypofractionated Radiotherapy, Normofractionated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck | Not applicable | Not yet recruiting | Assiut University | 60 | 2026-10-01 | 2026-09-29 |
| Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. A single-arm, single-center clinical trial evaluating efficacy - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Enrolling by invitation | Zhejiang Provincial People's Hospital | 30 | 2026-05-01 | 2026-04-24 |
| Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC Ficerafusp alfa, Pembrolizumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-26 | 2026-03-27 |
| Cisplatin-induced Cochlear and Vestibular Damage in Head and Neck Cancer Ototoxic Hearing Loss, Ototoxicity, Drug-Induced | Recruiting | Simon Jäger | 55 | 2026-01-20 | 2026-10-20 | |
| De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma De-escalation surgery, Standard Surgery, radiotherapy - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Not yet recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 356 | 2026-01-01 | 2026-01-06 |
| Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. Green Tea Extract with Morphine, Active Comparator: Triple Mixture Oral Rinse for Radiation-Induced Mucositis - Squamous Cell Carcinoma of the Head and Neck, Oral Mucositis | Phase 1 / Phase 2 | Not yet recruiting | Fundacion Clinica Valle del Lili | 40 | 2025-12-28 | 2025-04-01 |
| Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers GCP intratumoral catheter - Squamous Cell Carcinoma of the Head and Neck, Paclitaxel | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire, Amiens | 39 | 2025-11-01 | 2025-03-21 |
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer Docetaxel, Cisplatin, PRGN-2009 - Squamous Cell Carcinoma of the Head and Neck, Oropharynx | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-10 | 2026-10-19 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | 19 | 2023-12-12 | 2025-05-09 |
| A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors PF-08046052 - Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 68 | 2023-11-14 | 2026-05-05 |
| Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas Multiparameter analysis of each sample - Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Anus | Recruiting | National Cancer Institute, Naples | 170 | 2023-09-25 | 2025-07-29 | |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies JANX008 - Non-Small Cell Lung Cancer, Renal Cell Carcinoma | Phase 1 | Active not recruiting | Janux Therapeutics | 130 | 2023-04-19 | 2026-06-01 |
| A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Atezolizumab, Tiragolumab, Carboplatin - Squamous Cell Carcinoma of the Head and Neck | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 12 | 2023-04-12 | 2025-09-15 |
| A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN MRG003, Cetuximab injection, Methotrexate Injection - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Recruiting | Lepu Biopharma Co., Ltd. | 180 | 2023-04-04 | 2026-09-04 |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors PF-08046054, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Recruiting | Seagen, a wholly owned subsidiary of Pfizer | 714 | 2022-10-25 | 2026-07-22 |
| Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer cRGD-ZW800-1. - Squamous Cell Carcinoma of the Head and Neck, Oral Cancer | Phase 2 | Completed | Erasmus Medical Center | 31 | 2022-07-12 | 2026-09-14 |
| Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer Modi-1 Moditope, Pembrolizumab, MicronJet600™ microneedle device (NanoPass) - Triple Negative Breast Cancer, Renal Cell Cancer | Phase 1 / Phase 2 | Recruiting | Scancell Ltd | 168 | 2022-04-07 | 2025-09-17 |
Showing 20 of 180. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (180) · Carcinoma, Non-Small-Cell Lung (32) · Head and Neck Neoplasms (32) · Melanoma (22) · Carcinoma, Squamous Cell (21) · Carcinoma, Renal Cell (19) · Neoplasm Metastasis (18) · Colorectal Neoplasms (16) · Ovarian Neoplasms (15) · Neoplasms (14) · Carcinoma, Transitional Cell (11) · Endometrial Neoplasms (11) · Recurrence (11) · Triple Negative Breast Neoplasms (10) · Carcinoma (9)
Neoplasms by Histologic Type (180) · Neoplasms by Site (180) · Neoplasms, Glandular and Epithelial (180) · Carcinoma (171) · Neoplasms (166) · Carcinoma, Squamous Cell (159) · Head and Neck Neoplasms (148) · Respiratory Tract Diseases (36) · Lung Diseases (34) · Respiratory Tract Neoplasms (34) · Thoracic Neoplasms (34) · Bronchial Neoplasms (32) · Carcinoma, Bronchogenic (32) · Skin Diseases (31) · Skin and Connective Tissue Diseases (31)
Cisplatin (33) · Cetuximab (32) · pembrolizumab (25) · Carboplatin (18) · Radiotherapy (17) · Nivolumab (14) · Paclitaxel (11) · Fluorouracil (9) · Radiotherapy, Intensity-Modulated (8) · Ipilimumab (7) · durvalumab (7) · Docetaxel (6) · Methotrexate (5) · Albumin-Bound Paclitaxel (4) · Drug Therapy (4)
Dana-Farber Cancer Institute (6) · Pfizer (6) · Washington University School of Medicine (6) · AstraZeneca (4) · Bristol-Myers Squibb (4) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (4) · Merck KGaA, Darmstadt, Germany (4) · University of Arkansas (4) · Groupe Oncologie Radiotherapie Tete et Cou (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Seagen, a wholly owned subsidiary of Pfizer (3) · University of Chicago (3) · University of Michigan Rogel Cancer Center (3) · Xencor, Inc. (3) · Akamis Bio (2)
United States (116) · France (22) · Canada (16) · Spain (16) · Italy (14) · United Kingdom (14) · Belgium (13) · China (13) · Germany (13) · Japan (11) · Netherlands (10) · South Korea (10) · Australia (9) · Greece (8) · Switzerland (7)
Douglas Adkins, M.D. (3) · Jean-Pascal Machiels, MD, PhD (3) · Jared Weiss, MD (2) · K Mosterd, MD, PhD (2) · Paul Swiecicki, M.D. (2) · A. Dimitrios Colevas, MD (1) · Aiat M Mohammed, Doctor (1) · Alexander Pearson, M.D. (1)
PMID 36897458, PMID 12927569, PMID 16476835, PMID 18054441, PMID 18834631, PMID 20539208, PMID 21123824, PMID 21284052, PMID 21798893, PMID 22057678, PMID 22075702, PMID 22109700, PMID 22960745, PMID 23479384, PMID 23734882, PMID 23786302, PMID 24710768, PMID 24727329, PMID 24801836, PMID 25279959, PMID 25680594, PMID 25937431, PMID 26561342, PMID 26579227, PMID 26705063, PMID 27568350, PMID 27698593, PMID 27718784, PMID 27884140, PMID 27903924, PMID 28559019, PMID 28651929, PMID 28797458, PMID 28939066, PMID 29884413, PMID 30001987, PMID 30941307, PMID 30944020, PMID 30972702, PMID 31400383, PMID 31422216, PMID 31878938, PMID 32583557, PMID 32665297, PMID 32758455, PMID 33433743, PMID 33683482, PMID 33684371, PMID 33714009, PMID 33794205
2017 (3), 2014 (2), 2015 (2), 2016 (2), 2019 (2), 2018 (1), 2023 (1), P30CA124435 (1), R01CA184153 (1), R01CA190306 (1), R01DE015324 (1), R21CA130241 (1)